CellStories Bio
CellStories Bio is building patient-informed preclinical models designed to reveal how different patients respond before therapies reach the clinic.
Partner with usThe problem
Mouse and cell-based models do not fully capture the complexity of human disease. Promising preclinical findings too often fail to translate into clinical benefit.
In heterogeneous diseases, patients with the same diagnosis can differ substantially in their clinical history, symptoms and response to treatment. Average treatment effects can mask meaningful differences between patient subgroups.
We believe that understanding whether a therapy works starts with understanding whom it works for. By integrating clinical history, symptom profiles and patient experience with patient-derived models, we aim to identify subgroups most likely to benefit, and inform patient selection for clinical trials.
Our Platform
A streamlined preclinical testing platform that reveals how real human biology responds and who is most likely to benefit.
Your promising small-molecule candidate
Patient-derived organoids
Test compound across multiple conditions
Multi-omics and phenotypic readouts
AI-enabled analyses to find patterns
Identify likely responders
Our focus
Conditions that affect half the population remain some of the least funded, least studied areas in medicine.
Fibroids, endometriosis, and other reproductive conditions affect millions, yet the research base behind them is a fraction of what conditions of comparable prevalence receive elsewhere in medicine.
of all global R&D funding went to women's health research in 2020
of U.S. Alzheimer’s research funding targets women, who make up two-thirds of patients
of cardiovascular clinical trial participants in Europe are women, despite heart disease being a leading cause of death among them
McKinsey Health Institute · Women's Health Access Matters (WHAM) · European Society of Cardiology
Our first focus is uterine fibroids.
We’re building patient-derived 3D uterine models to capture the complexity and heterogeneity of fibrotic disease, creating a more human-relevant system for testing therapies and understanding differences in response.
Our goal is to build better preclinical models that support stronger clinical decisions. By combining patient-derived biology with clinical context, we aim to identify promising candidates, understand treatment response and guide what advances.
Our ambition is an AI-powered platform that predicts how patient groups respond to molecules, screening candidates, uncovering therapeutic possibilities and revisiting compounds conventional models may have overlooked.
About CellStories Bio
We are an early-stage TechBio company building higher-fidelity preclinical testing models. An experimental evidence layer between drug discovery and clinical development, designed around the biological differences that make us human.
Our platform is in development. We aim to support better-informed decisions; we do not claim validated clinical prediction.
We are looking for biotech, pharmaceutical and scientific partners interested in generating more human-relevant preclinical evidence.
